Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

Berobenatide shows promise for monthly GLP-1 dosing

NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or overweight, with and without type 2…